These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 26818741)

  • 21. Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing.
    Todesco E; Rodriguez C; Morand-Joubert L; Mercier-Darty M; Desire N; Wirden M; Girard PM; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2015 May; 70(5):1503-6. PubMed ID: 25614045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV-infected patients.
    Néant N; Lê MP; Bouazza N; Gattacceca F; Yazdanpanah Y; Dhiver C; Bregigeon S; Mokhtari S; Peytavin G; Tamalet C; Descamps D; Lacarelle B; Solas C
    Br J Clin Pharmacol; 2020 Dec; 86(12):2404-2413. PubMed ID: 32374049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART.
    Nouchi A; Nguyen T; Valantin MA; Simon A; Sayon S; Agher R; Calvez V; Katlama C; Marcelin AG; Soulie C
    J Antimicrob Chemother; 2018 Aug; 73(8):2141-2146. PubMed ID: 29846589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emtricitabine/tenofovir alafenamide (Descovy) for HIV.
    Med Lett Drugs Ther; 2016 Aug; 58(1500):100-1. PubMed ID: 27466750
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.
    Porter DP; Toma J; Tan Y; Solberg O; Cai S; Kulkarni R; Andreatta K; Lie Y; Chuck SK; Palella F; Miller MD; White KL
    HIV Clin Trials; 2016 Feb; 17(1):29-37. PubMed ID: 26899540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen.
    Dimeglio C; Raymond S; Nicot F; Jeanne N; Carcenac R; Lefebvre C; Izopet J;
    J Antimicrob Chemother; 2019 Mar; 74(3):718-721. PubMed ID: 30535228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Odefsey--another NNRTI combination for HIV.
    Med Lett Drugs Ther; 2016 May; 58(1494):60-1. PubMed ID: 27148923
    [No Abstract]   [Full Text] [Related]  

  • 28. Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen.
    Raymond S; Nicot F; Pallier C; Bellecave P; Maillard A; Trabaud MA; Morand-Joubert L; Rodallec A; Amiel C; Mourez T; Bocket L; Beby-Defaux A; Bouvier-Alias M; Lambert-Niclot S; Charpentier C; Malve B; Mirand A; Dina J; Le Guillou-Guillemette H; Marque-Juillet S; Signori-Schmuck A; Barin F; Si-Mohamed A; Avettand Fenoel V; Roussel C; Calvez V; Saune K; Marcelin AG; Rodriguez C; Descamps D; Izopet J;
    Clin Infect Dis; 2018 May; 66(10):1588-1594. PubMed ID: 29244143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
    Tebas P; Sension M; Arribas J; Duiculescu D; Florence E; Hung CC; Wilkin T; Vanveggel S; Stevens M; Deckx H;
    Clin Infect Dis; 2014 Aug; 59(3):425-34. PubMed ID: 24729492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biktarvy--another INSTI-based combination for HIV.
    Med Lett Drugs Ther; 2018 Aug; 60(1553):132-135. PubMed ID: 30133424
    [No Abstract]   [Full Text] [Related]  

  • 31. Emtricitabine + tenofovir alafenamide for the treatment of HIV.
    Corado KC; Daar ES
    Expert Opin Pharmacother; 2017 Mar; 18(4):427-432. PubMed ID: 28151023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
    Lambert-Niclot S; Charpentier C; Storto A; Fofana DB; Soulié C; Fourati S; Visseaux B; Wirden M; Morand-Joubert L; Masquelier B; Flandre P; Calvez V; Descamps D; Marcelin AG
    J Antimicrob Chemother; 2013 Jun; 68(6):1237-42. PubMed ID: 23361642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Viral blips were infrequent in treatment-naive adults treated with rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF through 96 weeks.
    Porter DP; Kulkarni R; Garner W; Miller MD; White KL
    Antivir Ther; 2017; 22(6):495-502. PubMed ID: 28091393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.
    Allavena C; Dailly E; Reliquet V; Bonnet B; Pineau S; André-Garnier E; Boutoille D; Bouquié R; Raveleau A; Bouchez S; Billaud E; Raffi F
    J Antimicrob Chemother; 2014 Oct; 69(10):2804-8. PubMed ID: 24907142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
    Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
    Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deep sequencing analysis of HIV-1 reverse transcriptase at baseline and time of failure in patients receiving rilpivirine in the phase III studies ECHO and THRIVE.
    Van Eygen V; Thys K; Van Hove C; Rimsky LT; De Meyer S; Aerssens J; Picchio G; Vingerhoets J
    J Med Virol; 2016 May; 88(5):798-806. PubMed ID: 26412111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
    HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
    Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
    Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C
    J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study.
    Porter DP; Daeumer M; Thielen A; Chang S; Martin R; Cohen C; Miller MD; White KL
    Viruses; 2015 Dec; 7(12):6360-70. PubMed ID: 26690199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.